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OBJECTIVE: Immunosuppressed patients are at risk of microsporidiosis, and this parasitosis has an increased rate of
dissemination in this population. Our objective was to evaluate the presence of microsporidiosis and other intestinal parasites
in rheumatic disease patients undergoing anti-tumor necrosis factor/disease-modifying anti-rheumatic drug treatment.
METHODS: Ninety-eight patients (47 with rheumatoid arthritis, 31 with ankylosing spondylitis and 11 with psoriatic
arthritis) and 92 healthy control patients were enrolled in the study. Three stool samples and cultures were collected
from each subject.
RESULTS: The frequency of microsporidia was significantly higher in rheumatic disease patients than in control
subjects (36 vs. 4%, respectively; p,0.0001), as well as in those with rheumatic diseases (32 vs. 4%, respectively;
p,0.0001), ankylosing spondylitis (45 vs. 4%, respectively; p,0.0001) and psoriatic arthritis (40 vs. 4%, respectively;
p,0.0001), despite a similar social-economic class distribution in both the patient and control groups (p=0.1153). Of
note, concomitant fecal leukocytes were observed in the majority of the microsporidia-positive patients (79.5%).
Approximately 80% of the patients had gastrointestinal symptoms, such as diarrhea (26%), abdominal pain (31%)
and weight loss (5%), although the frequencies of these symptoms were comparable in patients with and without
this infection (p.0.05). Rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis disease activity
parameters were comparable in both groups (p.0.05). The duration of anti-tumor necrosis factor/disease-
modifying anti-rheumatic drugs and glucocorticoid use were also similar in both groups.
CONCLUSION: We have documented that microsporidiosis with intestinal mucosa disruption is frequent in patients
undergoing concomitant anti-tumor necrosis factor/disease-modifying anti-rheumatic drug therapy. Impaired host
defenses due to the combination of the underlying disease and the immunosuppressive therapy is the most likely
explanation for this finding, and this increased susceptibility reinforces the need for the investigation of
microsporidia and implementation of treatment strategies in this population.
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Microsporidia has emerged in recent years as an opportu-
nistic infectious agent with a ubiquitous distribution.
1-4 The
clinical manifestations of this infection vary widely, from
none (asymptomatic) tonon-bloody waterydiarrhea,abdom-
inal cramps, weight loss, and disseminated disease, espe-
cially in immunosuppressed subjects.
2-4
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1171This parasitological disease primarily affects immuno-
suppressed patients,
1-4 particularly those with human
immunodeficiency virus (HIV), malignancies and diabetes
mellitus, as well as patients post heart-lung, liver, and renal
transplantations.
1,2 In addition, this infection also occurs in
patients undergoing immunosuppressive drug treatment.
2,4
In fact, patients with rheumatic diseases who are taking
disease-modifying anti-rheumatic drugs (DMARD) and
anti-tumor necrosis factor (TNF) therapy have a high risk
for general infections,
5-7 including intestinal pathogenic
parasite infestations such as Strongyloides stercoralis.
8,9
However, to our knowledge, there are no data regarding
the risk of microsporidiosis in these patients.
10-13
Therefore, the objective of this study was to evaluate the
frequency and clinical significance of microsporidiosis in
patients with rheumatic diseases who are undergoing anti-
TNF/DMARD treatment compared to an age- and socio-
economic condition-matched healthy population.
MATERIALS AND METHODS
We evaluated 89 consecutive patients at our hospital who
were diagnosed with rheumatoid arthritis (RA) (American
College of Rheumatology criteria),
14 ankylosing spondylitis
(AS) (New York criteria),
15 or psoriatic arthritis (PsA)
(European spondyloarthropathy Study Group – ESSG
criteria and Moll and Wright classification).
16 All patients
were undergoing anti-TNF therapy (adalimumab, etaner-
cept, or infliximab) combined with DMARDs. The control
group included 92 healthy employees of our hospital who
were matched by age and socio-economic status. Prior to
this study, no specific routine existed in our Infusion Center
with regard to stool examination for parasites and fecal
leukocytes before anti-TNF therapy. The prophylactic use of
anti-helminthic drugs was recommended for patients under
concomitant glucocorticoid therapy.
This study was approved by the local ethics committee,
and informed consent was obtained from each participant
or his or her legal guardian.
Demographic data, the number of school years attended,
and the socio-economic status (according to Associac ¸a ˜o
Brasileira dos Institutos de Pesquisa de Mercados)
17 were
recorded. Background information and parasitosis symp-
toms in patients and control participants were acquired
via interview and included the following: general (loss of
appetite, weight loss, and adynamia), gastrointestinal
(abdominal pain, abdominal distension, flatulence, diarrhea,
dysentery, tenesmus, obstipation, nausea, vomiting, hema-
tochezia, and worm elimination), cutaneous (exanthema),
and pulmonary manifestations (wheezing, thoracic pain,
and hemoptysis).
Disease activity and laboratory evaluation of
rheumatic diseases
Disease activity was evaluated by the following: the
duration of morning stiffness, the number of swollen and/
or painful joints, and the disease activity score (DAS28) for
RA patients
18 and the number of swollen and/or painful
joints and the Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI)
19 for AS and PsA patients.
The laboratory parameters assessed included the erythro-
cyte sedimentation rate (ESR) according to Westergreen
(mm/
1st hour) and C-reactive protein (CRP) level deter-
mined by nephelometry (mg/L). Data concerning current
treatment with prednisone, DMARDs, anti-TNF and immu-
nosuppressive drugs (methotrexate, azathioprine, lefluno-
mide, chloroquine, sulfasalazine and/or cyclosporine) were
collected.
Parasitological assessment
Three stool samples were collected from rheumatic
disease patients and control subjects on different days and
placed into plastic vials without preservatives. The stool
samples were microscopically analyzed for the detection of
protozoan oocysts, cysts, helminth eggs, and larvae by a
qualified technician blinded to the groups using the
techniques described by Faust et al, Rugai and Lutz
(modified), and Hoffman, Pons and Janer.
20
Microsporidia positivity was defined as the isolation of
at least one parasite using the GRAM-Chromotrope
21
technique.
Intestinal coccidia were evaluated by the GRAM-
Chromotrope
21 technique; Leishman staining
22 was used
to identify Blastocystis hominis and fecal leukocytes; the
Kinyoun procedure
23 and capture enzyme-linked immuno-
sorbent assay (capture ELISA) were used to detect
Cryptosporidium sp., Cyclospora cayetanensis, and Isospora belli;
and Kato-Katz was used to detect Schistosoma mansoni.
24
Coproculture was also performed using SS agar,
MacConkey agar or Karmali plate agar.
25
Giardia lamblia, Strongyloides stercoralis, Ancilostoma duode-
nali, Ascaris lumbricoides, Entamoeba histolytica, Microsporidia
(positive stool leukocytes), Entamoeba dispar, Dientamoeba
fragilis, Cryptosporidium parvum, Cyclospora cayetanensis,
Isospora belli, and Blastocystis hominis (positive stool leuko-
cytes) were defined as pathogenic parasites in immuno-
compromised patients.
1 All participants with positive




Results are presented as the mean ¡ standard deviation
or the median (range) for continuous variables and the
number (%) for categorical variables. Continuous variables
were compared using the t test and the Mann Whitney test
to evaluate differences between patients with and without
intestinal microsporidia and other parasitoses. For catego-
rical variables, differences in proportions were assessed by
Fisher’s exact test. For all statistical tests, significance was
set at a p-value ,0.05.
RESULTS
A total of 89 patients with rheumatic diseases (47 RA, 31
AS and 11 PsA) and 92 healthy control subjects were
included in this study. The two groups were comparable
with regard to the mean current age (47.2¡10.9 vs.
43.8¡14.3 years, respectively; p=0.094), percentage who
were Caucasian (80 vs. 73%, respectively; p=0.3) and
socio-economic distribution, with a similar predominance
of the middle and lowest Brazilian socio-economic classes
(C, D or E)
17 based on scholarity and ownership of
household items (84 vs. 82%, respectively; p=0.7). There
were a greater proportion of females in the control group
than in the patient group (93 vs. 62%, respectively;
p,0.0001). The mean disease duration for all patients
was 15.5¡8.6 years.
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1172Intestinal parasites
The overall frequency of pathogenic parasites was similar
in both the patient and control groups (63 vs. 58%,
respectively; p=0.54). Positive tests for microsporidia were
significantly higher in all types of rheumatic disease
patients compared with the control subjects (38 vs. 4%,
respectively; p,0.0001), and microsporidia plus positive
fecal leukocytes were also more frequently detected in
patients than in control subjects (31 vs. 4%, respectively;
p,0.0001). Of note, 81.6% of the positive microsporidia
patients had concomitant fecal leukocytes. In contrast, no
differences were detected for other pathogenic parasites
(Entamoeba histolytica/dispar, Dientamoeba fragilis, Giardia
lamblia, Cryptosporidium parvum, Cyclospora cayetanensis,
Isospora belli, Ancilostoma duodenale, Ascaris lumbricoides,
and Blastocystis hominis with leukocytes) and non-patho-
genic parasites (Endolimax nana, Entamoeba coli, and
Entamoeba hartmanni)( p.0.05; Table 1). Among the 28
patients with microsporidia and positive stool leukocytes,
36% had other concomitant pathogenic parasites, particu-
larly Blastocystis hominis [8/28 (29%) patients]; however, no
association of microsporidia and Blatocystis hominis was
observed (p=0.28). Regarding the prevalence of pathogenic
parasites in each disease compared to the control group,
microsporidiosis was higher in RA (32 vs. 4%, respectively;
p,0.0001), AS (45 vs. 4%, respectively; p,0.0001) and PsA
patients (40 vs. 4%, respectively; p,0.0001). Moreover, there
were no statistical differences in microsporidia positivity
between the specific diseases (RA vs. AS and PsA; AS vs.
PsA; all p.0.05). Giardia lamblia was significantly more
common in AS patients vs. control subjects (10% vs. 0%,
respectively; p=0.0149), whereas no differences were
observed for the other pathogenic parasites (p.0.05).
Disease activity parameters at the study onset were alike in
patients with and without microsporidia infections for all
diseases (RA, AS, and PsA) (p.0.05). The analysis of the
duration of anti-TNF/DMARD therapy showed no statistical
difference between patients with and without microsporidia
infection (p=0.55). The frequencies of glucocorticoid use in
patients with and without microsporidiosis [44% (95% IC
0.27-0.62) vs. 64% (95% IC 0.49-0.76); p=0.08] were alike, as
was the number of DMARDs used (Table 2).
Table 1 - Intestinal parasites in rheumatic disease patients










Microsporidia 34 (38) 4 (4) ,0.0001
Microsporidia with
leukocytes
28 (31) 4 (4) ,0.0001
Entamoeba histolytica/
dispar
0 (0) 4 (4) 0.12
Dientamoeba fragilis 3 (3) 0 (0) 0.12
Giardia lamblia 3 (3) 0 (0) 0.12
Strongyloides stercoralis 3 (3) 2 (2) 0.68
Cryptosporidium parvum 3 (3) 5 (5) 0.72
Cyclospora cayetanensis 0 (0) 0 (0) 1.0
Isospora belli 0 (0) 0 (0) 1.0
Ancilostoma duodenale 1 (1) 0 (0) 0.49
Ascaris lumbricoides 0 (0) 0 (0) 1.0
Blastocystis hominis with
leukocytes
46 (52) 42 (46) 0.46
Non-pathogenic parasites
Endolimax nana 17 (19) 25 (27) 0.22
Entamoeba coli 6 (7) 12 (13) 0.21
Entamoeba hartmanni 1 (1) 1 (1) 0.5
Results arepresentedas n(%);DMARDs- disease-modifyinganti-rheumatic
drugs.
Table 2 - Disease activity parameters and treatments in patients with rheumatic diseases undergoing anti-TNF and
DMARD therapies with and without microsporidia infection.
Parameters Patients with microsporidia (n=34) Patients without microsporidia (n=55) p-value
Rheumatoid arthritis (n=47)
Morning stiffness, minutes 13¡17.9 26.9¡43.2 0.24
Number of painful joints 6.5¡5.8 11¡10 0.12
Number of swollen joints 4.8¡5.1 5.1¡4.1 0.83
DAS28 3.8¡1.6 4.6¡1.3 0.10
ESR, mm/1
st hour 26.6¡26.1 27.1¡15.5 0.94
CRP, mg/L 8.49¡9.5 15.4¡17.9 0.19
Ankylosing spondylitis (n=31)
Number of painful joints 5.6¡13.4 3.6¡4.2 0.59
Number of swollen joints 1.4¡1.4 1.7¡2.3 0.68
BASDAI 3.48¡2.01 3.47¡2.43 0.99
ESR, mm/1
st hour 23¡27 14¡16 0.27
CRP, mg/L 12.6¡14.5 13.2¡21.1 0.94
Psoriatic arthritis (n=11)
Morning stiffness (minutes) 0 (0-20) 17.5 (0-120) 0.14
Number of painful joints 5 (0-8) 3.5 (0-12) 0.93
Number of swollen joints 1 (0-2) 1 (0-2) 0.77
BASDAI 2.33 (0-6.98) 4.06 (0.27-5.16) 0.48
ESR, mm/1
st hour 11.5 (3-76) 23(1-46) 0.73
CRP, mg/L 2 (0.2-19.6) 6.8 (1.5-32.5) 0.55
Rheumatic patients treated (n=89)
Anti-TNF and DMARD therapy duration
(months)
15¡11.7 13.6¡9.7 0.55
Glucocorticoid use 15 (44) 35 (64) 0.08
Methotrexate use 26 (76) 33 (60) 0.17
Number of DMARDs 1.1¡0.7 0.9¡0.7 0.33
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1173No differences were detected in the frequencies of other
infections that required antibiotic therapy in patients with
and without microsporidiosis, such as acute lower respira-
tory infection (2.9 vs. 14.5%, respectively; p=0.14), urinary
tract infection (29.4 vs. 30.9%, respectively; p=1.0) cuta-
neous infection (20.6 vs. 23.6%, respectively; p=0.8) and
tuberculosis (2.9 vs. 1.8%, respectively; p=1.0).
The comparison of rheumatic disease patients with and
without microsporidiosis revealed that 85.4% of the patients
had gastrointestinal symptoms such as diarrhea (19%),
abdominal pain (22%), and weight loss (11%), but these
symptoms occurred just as frequently in patients with and
without this infection (p.0.05). Other signs and symptoms
related to parasitoses were also comparable in the two
groups, with the exception of abdominal distension
(p=0.013) and adynamia (p=0.009), both of which occurred
less often in patients with microsporidiosis (Table 3). No
patient or control group had a disseminated infection.
DISCUSSION
This study is the first to identify a high frequency of
microsporidia infections associated with intestinal mucosa
disruption in rheumatic disease patients undergoing anti-
TNF and DMARD therapies.
The study design has several advantages, including the
inclusion of patients with well-established rheumatic disease
criteria.
14-16 In addition, the Gram-Chromotrope stain meth-
odology applied in this study is considered to be one of the
most specific detection techniques with the best sensitivity
for detecting microsporidia in fluids, including feces.
2
Moreover, external factors such as socio-economic conditions
may influence parasitosis prevalence. For example, the
frequency of microsporidia in HIV-infected patients was
higher in Venezuela (13.6%), an underdeveloped country,
than in Italy (1.8%).
27-28 This potential bias was greatly
reduced by the matching of our patients with a control group
with the same socio-financial distribution. One limitation of
our study was the absence of a control group of rheumatic
disease patients treated only with DMARDs, due to the
impossibility of achieving an adequate matching for disease
duration and severity in these patients. In fact, anti-TNF
therapy is now being indicated very early for patients with
these diseases. There are, however, no data on the frequency
of microsporidia infection in rheumatic disease patients
without anti-TNF therapy.
Microsporidia has emerged as an important cause of
infectious complications in severely immunocompromised
patients with HIV, recipients of solid organ transplant and
patients with hematological malignancies.
1-3 Cell-mediated
immunity appears to be critical for protection against
microsporidia through the T helper cell 1 (Th1) cytokine
response.
3 The importance of a Th1 response in the
resistance to microsporidial infection has been demon-
strated by in vitro studies showing that knockout animals
for Th1 cytokines such as interferon and interleukin-12
could not clear microsporidia infections.
29 In fact, more
severe microsporidia infections were observed in HIV-
infected patients with declining CD4+ and CD8+ T-cell
numbers.
29 Accordingly, the inhibition of TNF-alpha, a
cytokine well known to be related to the Th1 response,
30
could possibly facilitate the microsporidia infestation
observed in the present study. Moreover, experimental
studies have reported a decrease in the specific protective
IgG against microsporidia in animals treated with immu-
nosuppressive drugs.
31 We have confirmed that microspor-
idia infestation is more prevalent in immunosuppressed
patients
1-4 and have now extended this observation to
rheumatic disease patients undergoing anti-TNF/DMARD
treatment.
Microsporidiosis and intestinal parasitosis may present
with diverse clinical manifestations, depending on the host
immune status and the microsporidium species.
1-4
Diarrhea and wasting syndromes are the most common
complaints;
1-4 however, these parasite infections can be
asymptomatic. In fact, the parasitosis in our study was
frequently associated with gastrointestinal manifestations
and concomitant stool leukocytes, indicating a possible
intestinal mucosa disruption,
32 which is a known risk for
intestinal dissemination.
33
Infection is a major co-morbidity in rheumatic conditions,
and therapies such as conventional DMARDs and anti-TNF
are known to enhance the risk of infection.
34,35 In this regard,
previous reports have suggested that susceptibility to
infection may be distinct in different underlying rheumatic
diseases. The main explanation for this finding seems to be a
disease-associated genetic background and immunosuppres-
sive therapy.
36,37 However, in the present study, no differ-
ence was observed in microsporidiosis frequency between
the specific rheumatic diseases, suggesting that anti-TNF/
DMARD treatment is a more relevant risk factor for this
infestation than is the specific rheumatic disease itself.
We have identified microsporidiosis to be a frequent
infection that is associated with mucosal lesions in patients
undergoing concomitant anti-TNF/DMARD treatment. This
finding supports the notion that the recommendation for the
prophylactic use of anti-helminthic drugs in patients on
Table 3 - Clinical manifestations in patients with
rheumatic diseases undergoing anti-TNF and DMARD









Abdominal pain 10 (29) 10 (18) 0.296
Diarrhea 10 (29) 7 (13) 0.094
Weight loss 2 (6) 8 (15) 0.306
Nausea 8 (24) 14 (25) 1.0
Vomit 6 (18) 8 (15) 0.768
Flatulence 6 (18) 19 (35) 0.096
Dysentery 2 (6) 0 (0) 0.143
Tenesmus 0 (0) 4 (7) 0.294
Obstipation 6 (18) 9 (16) 1.0
Loss of appetite 7 (21) 6 (11) 0.231
Hematochezia 2 (6) 5 (9) 0.704
Worm elimination 0 (0) 5 (9) 0.152
Wheezing 8 (24) 5 (9) 0.072
Thoracic pain 8 (24) 6 (11) 0.139
Hemoptysis 2 (6) 2 (4) 0.635
Exanthema 2 (6) 10 (18) 0.121
Abdominal
distension
2 (6) 15 (27) 0.013
Adynamia 11 (32) 34 (62) 0.009
Any gastrointestinal
symptom
29 (85) 47 (85) 1.0
Systemic
dissemination
0 (0) 0 (0) 1.0
Results arepresentedasn(%);DMARDs- disease-modifyinganti-rheumatic
drugs.
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anti-TNF therapy.
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